1Nakaji S, Yamamoto T. Membranes for therapeutic apheresis. Ther Apher,2002,6:267.
2Yokoyama H, Wads T, Furuichi K. Immunomodulation effects and clinical evidence of apheresis in renal diseases. Ther Apher Dial, 2003,7 : 497.
3Yeh JH, Chen WH, Chiu HC. Hemodynamic effects of the different vascular accesses used for double-filtration plasmapheresis.J Clin Apheresis,2001,16:125.
4Kaplan AA. Therapeutic apheresis for renal disorders. Ther Apher, 1999,3:25.
5Russo GE, Bonello M, Bauco B, et al. Nephrotic syndrome and plasmapheresis. Int J Artif Organs, 2000 Feb, 23: 111.
6Tanabe K, Tokumoto T, Ishida H, et al. ABO-incompatible renal transplantation at Tokyo Women's Medical University. Clin Transpl, 2003,175.
7Otsubo S, Tanabe K, Shinmura H, et al. Effect of post-transplant doubl filtration plasmapheresis on recurrent focal and segmental glomerulosclerosis in renal transplant recipients. Ther Apher Dial,2004,8 :299.
8Siami GA, Siami FS. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher, 2001,5:315.
10Lin SM, Yeh JH, Lee CC,et al. Clearance of fibfinogen and von Willebrand factor in serial double-filtration plasmaphereais J Clin Apheresis, 2003,18: 67.
